Jason Keyes has served as a director of Actuate Therapeutics since August 2024 and chairs its audit committee. He has served as Chief Financial Officer of BlossomHill Therapeutics, Inc. since May 2025, and was previously Chief Financial Officer of Equillium, Inc. from March 2018 to April 2025. Earlier he served in various roles, including Executive Vice President and Chief Financial Officer, at Orexigen Therapeutics, Inc. from 2013 to 2018, and in finance leadership roles at Amylin Pharmaceuticals (acquired by Bristol-Myers Squibb in 2012), Amgen, Inc. and Baxter Healthcare Corporation. He formerly served on the board and as audit committee chair of Sesen Bio, Inc. from 2020 to 2023. Mr. Keyes received B.S. and M.S. degrees in Civil Engineering from Stanford University and an M.B.A. from the UCLA Anderson School of Management.